Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia.
Gregorova J, Vlachova M, Vychytilova-Faltejskova P, Dostalova A, Ruzickova T, Vecera M, Radova L, Pospichalova V, Sladecek S, Hyzdalova M, Kotaskova J, Jarosova M, Masek J, Benesova K, Jarkovsky J, Rihova L, Bezdekova R, Almasi M, Boichuk I, Stork M, Pour L, Sevcikova S. Gregorova J, et al. Among authors: pour l. Hematol Oncol. 2025 Jan;43(1):e70036. doi: 10.1002/hon.70036. Hematol Oncol. 2025. PMID: 39804194 Free PMC article.
Successful treatment of relapsed Waldenström's macroglobulinemia with proteasome inhibitors (bortezomib and subsequently ixazomib) in combination with rituximab and dexamethasone. A case report and review of the of proteasome inhibitors in Waldenström's….
Adam Z, Krejčí M, Pour L, Weinbergerová B, Sandecká V, Štork M, Boichuk I, Řehák Z, Keřkovský M, Koukalová R, Zdražilová-Dubská L, Čechová B, Král Z. Adam Z, et al. Among authors: pour l. Klin Onkol. 2024;39(6):451-462. doi: 10.48095/ccko2024451. Klin Onkol. 2024. PMID: 39772826 Review. English.
Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months….
Čermák A, Foukal J, Řehák Z, Adam Z, Keřkovský M, Hruška L, Borský M, Doubek M, Vlažný J, Pavlovský Z, Chovancová Z, Boichuk I, Štork M, Pour L, Koukalová R, Tomíška M, Král Z. Čermák A, et al. Among authors: pour l. Klin Onkol. 2024;38(5):354-369. doi: 10.48095/ccko2024354. Klin Onkol. 2024. PMID: 39516034 English.
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.
Knop S, Szarejko M, Grząśko N, Bringhen S, Trautmann-Grill K, Jurczyszyn A, Vacca A, Khandanpour C, Gamberi B, Pour L, Iversen KF, Stumpp MT, Suter C, Dawson KM, Zitt C, Legenne P, Stavropoulou V, Fey MF, Leupin N, Goldschmidt H. Knop S, et al. Among authors: pour l. EJHaem. 2024 Aug 1;5(5):940-950. doi: 10.1002/jha2.968. eCollection 2024 Oct. EJHaem. 2024. PMID: 39415900 Free PMC article.
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.
Muronova L, Soucek O, Zihala D, Sevcikova T, Popkova T, Plonkova H, Venglar O, Pour L, Stork M, Rihova L, Bezdekova R, Minarik J, Látal V, Novak M, Jungova A, Dekojova T, Straub J, Spacek M, Rezacova V, Maisnar V, Radocha J, Hajek R, Jelinek T. Muronova L, et al. Among authors: pour l. Eur J Haematol. 2025 Jan;114(1):155-163. doi: 10.1111/ejh.14316. Epub 2024 Oct 10. Eur J Haematol. 2025. PMID: 39390851 Free PMC article.
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.
Stork M, Ondrouskova E, Bohunova M, Boichuk I, Fric D, Adam Z, Krejci M, Sandecka V, Knechtova Z, Radova L, Jelinkova Z, Adlerova T, Krticka M, Nekuda V, Borsky M, Sevcikova S, Jarosova M, Pour L. Stork M, et al. Among authors: pour l. Blood Cancer J. 2024 Aug 26;14(1):146. doi: 10.1038/s41408-024-01131-6. Blood Cancer J. 2024. PMID: 39187485 Free PMC article. No abstract available.
Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients.
Vlachová M, Pečinka L, Gregorová J, Moráň L, Růžičková T, Kovačovicová P, Almáši M, Pour L, Štork M, Hájek R, Jelínek T, Popková T, Večeřa M, Havel J, Vaňhara P, Ševčíková S. Vlachová M, et al. Among authors: pour l. Sci Rep. 2024 Aug 13;14(1):18777. doi: 10.1038/s41598-024-69408-1. Sci Rep. 2024. PMID: 39138296 Free PMC article.
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.
Yong K, Martin T, Dimopoulos MA, Mikhael J, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Yong K, et al. Among authors: pour l. Lancet Haematol. 2024 Oct;11(10):e741-e750. doi: 10.1016/S2352-3026(24)00148-0. Epub 2024 Jul 24. Lancet Haematol. 2024. PMID: 39067465 Clinical Trial.
280 results